Next generation metronomic chemotherapy-report from the Fifth
Biennial International Metronomic and Anti-angiogenic Therapy
Meeting, 6-8 May 2016, Mumbai

J 2016

Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai

PANTZIARKA, P., L. HUTCHINSON, N. ANDRE, S. BENZEKRY, F. BERTOLINI et. al.

Základní údaje

Originální název

Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai

Autoři

PANTZIARKA, P. (826 Velká Británie a Severní Irsko), L. HUTCHINSON (826 Velká Británie a Severní Irsko), N. ANDRE (250 Francie), S. BENZEKRY (250 Francie), F. BERTOLINI (380 Itálie), A. BHATTACHARJEE (356 Indie), S. CHIPLUNKAR (356 Indie), D.G. DUDA (840 Spojené státy), V. GOTA (356 Indie), S. GUPTA (356 Indie), A. JOSHI (356 Indie), S. KANNAN (356 Indie), R. KERBEL (124 Kanada), M. KIERAN (840 Spojené státy), A. PALAZZO (380 Itálie), A. PARIKH (356 Indie), E. PASQUIER (250 Francie), V. PATIL (356 Indie), K. PRABHASH (356 Indie), Y. SHAKED (376 Izrael), G.S. SHOLLER (840 Spojené státy), Jaroslav ŠTĚRBA (203 Česká republika, garant, domácí), D.J. WAXMAN (840 Spojené státy) a S. BANAVALI (356 Indie)

Vydání

Ecancermedicalscience, Briston, Cancer Intelligence, 2016, 1754-6605

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/16:00092090

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3332/ecancer.2016.689

UT WoS

000386723100001

Klíčová slova anglicky

Metronomic chemotherapy; drug repurposing; anti-angiogenics; cancer; LMIC

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 12. 2016 12:31, Soňa Böhmová

Anotace

V originále

The 5th Biennial Metronomic and Anti-angiogenic Therapy Meeting was held on 6th - 8th May in the Indian city of Mumbai. The meeting brought together a wide range of clinicians and researchers interested in metronomic chemotherapy, anti-angiogenics, drug repurposing and combinations thereof. Clinical experiences, including many from India, were reported and discussed in three symposia covering breast cancer, head and neck cancers and paediatrics. On the pre-clinical side research into putative mechanisms of action, and the interactions between low dose metronomic chemotherapy and angiogenesis and immune responses, were discussed in a number of presentations. Drug repurposing was discussed both in terms of clinical results, particularly with respect to angiosarcoma and high-risk neuroblastoma, and in pre-clinical settings, particularly the potential for peri-operative interventions. However, it was clear that there remain a number of key areas of challenge, particularly in terms of definitions, perceptions in the wider oncological community, mechanisms of action and predictive biomarkers. While the potential for metronomics and drug repurposing in low and middle income countries remains a key theme, it is clear that there is also considerable potential for clinically relevant improvements in patient outcomes even in high income economies.

Citovat

PANTZIARKA, P., L. HUTCHINSON, N. ANDRE, S. BENZEKRY, F. BERTOLINI, A. BHATTACHARJEE, S. CHIPLUNKAR, D.G. DUDA, V. GOTA, S. GUPTA, A. JOSHI, S. KANNAN, R. KERBEL, M. KIERAN, A. PALAZZO, A. PARIKH, E. PASQUIER, V. PATIL, K. PRABHASH, Y. SHAKED, G.S. SHOLLER, Jaroslav ŠTĚRBA, D.J. WAXMAN a S. BANAVALI. Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. Ecancermedicalscience. Briston: Cancer Intelligence, 2016, roč. 10, NOV 2 2016, s. 1-19. ISSN 1754-6605. Dostupné z: https://dx.doi.org/10.3332/ecancer.2016.689.

@article{1363075,
   author = {Pantziarka, P. and Hutchinson, L. and Andre, N. and Benzekry, S. and Bertolini, F. and Bhattacharjee, A. and Chiplunkar, S. and Duda, D.G. and Gota, V. and Gupta, S. and Joshi, A. and Kannan, S. and Kerbel, R. and Kieran, M. and Palazzo, A. and Parikh, A. and Pasquier, E. and Patil, V. and Prabhash, K. and Shaked, Y. and Sholler, G.S. and Štěrba, Jaroslav and Waxman, D.J. and Banavali, S.},
   article_location = {Briston},
   article_number = {NOV 2 2016},
   doi = {http://dx.doi.org/10.3332/ecancer.2016.689},
   keywords = {Metronomic chemotherapy; drug repurposing; anti-angiogenics; cancer; LMIC},
   language = {eng},
   issn = {1754-6605},
   journal = {Ecancermedicalscience},
   title = {Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai},
   volume = {10},
   year = {2016}
}

TY  - JOUR
ID  - 1363075
AU  - Pantziarka, P. - Hutchinson, L. - Andre, N. - Benzekry, S. - Bertolini, F. - Bhattacharjee, A. - Chiplunkar, S. - Duda, D.G. - Gota, V. - Gupta, S. - Joshi, A. - Kannan, S. - Kerbel, R. - Kieran, M. - Palazzo, A. - Parikh, A. - Pasquier, E. - Patil, V. - Prabhash, K. - Shaked, Y. - Sholler, G.S. - Štěrba, Jaroslav - Waxman, D.J. - Banavali, S.
PY  - 2016
TI  - Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai
JF  - Ecancermedicalscience
VL  - 10
IS  - NOV 2 2016
SP  - 1-19
EP  - 1-19
PB  - Cancer Intelligence
SN  - 17546605
KW  - Metronomic chemotherapy
KW  - drug repurposing
KW  - anti-angiogenics
KW  - cancer
KW  - LMIC
N2  - The 5th Biennial Metronomic and Anti-angiogenic Therapy Meeting was held on 6th - 8th May in the Indian city of Mumbai. The meeting brought together a wide range of clinicians and researchers interested in metronomic chemotherapy, anti-angiogenics, drug repurposing and combinations thereof. Clinical experiences, including many from India, were reported and discussed in three symposia covering breast cancer, head and neck cancers and paediatrics. On the pre-clinical side research into putative mechanisms of action, and the interactions between low dose metronomic chemotherapy and angiogenesis and immune responses, were discussed in a number of presentations. Drug repurposing was discussed both in terms of clinical results, particularly with respect to angiosarcoma and high-risk neuroblastoma, and in pre-clinical settings, particularly the potential for peri-operative interventions. However, it was clear that there remain a number of key areas of challenge, particularly in terms of definitions, perceptions in the wider oncological community, mechanisms of action and predictive biomarkers. While the potential for metronomics and drug repurposing in low and middle income countries remains a key theme, it is clear that there is also considerable potential for clinically relevant improvements in patient outcomes even in high income economies.
ER  -

PANTZIARKA, P., L. HUTCHINSON, N. ANDRE, S. BENZEKRY, F. BERTOLINI, A. BHATTACHARJEE, S. CHIPLUNKAR, D.G. DUDA, V. GOTA, S. GUPTA, A. JOSHI, S. KANNAN, R. KERBEL, M. KIERAN, A. PALAZZO, A. PARIKH, E. PASQUIER, V. PATIL, K. PRABHASH, Y. SHAKED, G.S. SHOLLER, Jaroslav ŠTĚRBA, D.J. WAXMAN a S. BANAVALI. Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. \textit{Ecancermedicalscience}. Briston: Cancer Intelligence, 2016, roč.~10, NOV 2 2016, s.~1-19. ISSN~1754-6605. Dostupné z: https://dx.doi.org/10.3332/ecancer.2016.689.

Podrobný výpis o publikaci